-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Maintains Buy on Apogee Therapeutics, Raises Price Target to $128

Benzinga·01/05/2026 11:09:52
語音播報
BTIG analyst Julian Harrison maintains Apogee Therapeutics (NASDAQ:APGE) with a Buy and raises the price target from $115 to $128.